Biocon Biologics gets EU approval for 2 drugs to treat bone cancer, osteoporosis and bone loss
- Posted on July 3, 2025
- By Financial Express
- 3 Views
Biocon Biologics gets EU approval for 2 drugs to treat bone cancer, osteoporosis and bone loss
Biocon Biologics, a subsidiary of Biocon, has secured EU marketing authorisation for its Denosumab biosimilars Vevzuo and Evfraxy, expanding treatment options for cancer-related bone disease and osteoporosis across Europe.
